Signify Premium Insight: The Concerted Effort that TeraRecon Must Make
Published: April 26, 2022
TeraRecon first became linked to ConcertAI after being acquired by corporate parent SymphonyAI in March 2020. This portfolio of companies seeking to develop new generation AI solutions across a variety of sectors, from retail to financial services, brought TeraRecon on board and placed it alongside stablemate ConcertAI. At the time the deal seemed to offer clear synergistic opportunities for both parties such combining population data from ConcertAI with imaging biomarker technology and expertise to improve patient stratification for oncology clinical trials. Alternatively, providers could utilise imaging data from TeraRecon alongside EHRs and real-world data from ConcertAI to develop more integrated care management solutions.
Read the full insight with a Signify Premium Insights – Medical Imaging subscriptionSign up for a free trial today.
Imaging IT – Market Intelligence ServiceOngoing series of reports, data and insights delivered over the year
Imaging IT – Market Intelligence Service
This Market Intelligence Service is an annual subscription that provides ongoing data, insights and analysis on the global opportunities for Imaging IT.
Find out more